Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$20.75 +2.7%	$16.90	$9.57 ▼ $27.34	$2.87B	0.94	1.95 million shs	2.42 million shs
IMVT Immunovant	$14.84 +0.1%	$16.41	$12.72 ▼ $34.47	$2.59B	0.66	1.46 million shs	1.10 million shs
KYMR Kymera Therapeutics	$42.59 +0.6%	$44.32	$19.44 ▼ $53.27	$3.05B	2.18	745,287 shs	524,452 shs
SVA Sinovac Biotech	$6.47	$6.47	$5.73 ▼ $8.75	$644.67M	0.61	N/A	N/A

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	+1.71%	+1.05%	+37.32%	+31.25%	-14.41%
IMVT Immunovant	0.00%	-6.73%	-16.27%	+1.79%	-52.98%
KYMR Kymera Therapeutics	-0.52%	+3.98%	-6.18%	+40.37%	-8.92%
SVA Sinovac Biotech	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.6993 of 5 stars	3.5	1.0	0.0	3.4	2.6	2.5	0.0
IMVT Immunovant	2.9164 of 5 stars	4.4	2.0	0.0	0.0	2.5	1.7	0.0
KYMR Kymera Therapeutics	3.0233 of 5 stars	4.6	1.0	0.0	0.0	2.6	2.5	0.0
SVA Sinovac Biotech	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	3.00	Buy	$43.14	107.92% Upside
IMVT Immunovant	2.83	Moderate Buy	$35.20	137.20% Upside
KYMR Kymera Therapeutics	3.10	Buy	$59.11	38.79% Upside
SVA Sinovac Biotech	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SVA, IMVT, KYMR, and ARWR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	IMVT Immunovant	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $37.00
8/12/2025	IMVT Immunovant	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$33.00 ➝ $30.00
8/11/2025	IMVT Immunovant	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/11/2025	ARWR Arrowhead Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/11/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00
8/8/2025	ARWR Arrowhead Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$40.00 ➝ $38.00
7/30/2025	KYMR Kymera Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$60.00
7/28/2025	ARWR Arrowhead Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/28/2025	IMVT Immunovant	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$17.00 ➝ $18.00
7/15/2025	KYMR Kymera Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/10/2025	IMVT Immunovant	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$18.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$3.55M	808.14	N/A	N/A	$3.76 per share	5.52
IMVT Immunovant	N/A	N/A	N/A	N/A	$3.49 per share	N/A
KYMR Kymera Therapeutics	$47.07M	64.69	N/A	N/A	$13.59 per share	3.13
SVA Sinovac Biotech	$448.27M	1.44	$0.17 per share	38.95	$120.83 per share	0.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.28	N/A	N/A	N/A	N/A	-40.91%	-11.62%	N/A
IMVT Immunovant	-$413.84M	-$2.85	N/A	N/A	N/A	N/A	-80.99%	-72.23%	11/6/2025 (Estimated)
KYMR Kymera Therapeutics	-$223.86M	-$3.47	N/A	N/A	N/A	-616.03%	-31.60%	-27.12%	10/30/2025 (Estimated)
SVA Sinovac Biotech	-$99.92M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest SVA, IMVT, KYMR, and ARWR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q1 2026	IMVT Immunovant	-$0.69	-$0.60	+$0.09	-$0.71	N/A	N/A
8/11/2025	Q2 2025	KYMR Kymera Therapeutics	-$0.83	-$0.95	-$0.12	-$0.95	$17.37 million	$11.48 million
8/7/2025	Q3 2025	ARWR Arrowhead Pharmaceuticals	-$0.94	-$1.26	-$0.32	-$1.26	$29.01 million	$27.77 million
5/29/2025	Q4 2025	IMVT Immunovant	-$0.72	-$0.64	+$0.08	-$0.64	N/A	$0.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
SVA Sinovac Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	0.39	4.87	4.87
IMVT Immunovant	N/A	12.32	12.32
KYMR Kymera Therapeutics	N/A	8.32	8.32
SVA Sinovac Biotech	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
IMVT Immunovant	47.08%
KYMR Kymera Therapeutics	N/A
SVA Sinovac Biotech	N/A

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
IMVT Immunovant	1.80%
KYMR Kymera Therapeutics	16.01%
SVA Sinovac Biotech	12.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.26 million	132.31 million	Optionable
IMVT Immunovant	120	174.32 million	171.18 million	Optionable
KYMR Kymera Therapeutics	170	71.50 million	60.05 million	Optionable
SVA Sinovac Biotech	3,261	99.64 million	86.89 million	Optionable

SVA, IMVT, KYMR, and ARWR Headlines

Recent News About These Companies

SINOVAC Board Sets the Record Straight on July 8 Special Meeting of ...

July 13, 2025 | morningstar.comM

SINOVAC Board of Directors Provides Update on Status of US$55.00 ...

July 11, 2025 | morningstar.comM

SINOVAC Board Sets the Record Straight on July 8 Special Meeting of Shareholders

July 11, 2025 | businesswire.com

Sinovac Biotech’s New Board Charts Future Path with Strategic Initiatives

July 11, 2025 | tipranks.com

Newly Elected Directors of Sinovac Hold the First Board Meeting

July 10, 2025 | financialpost.comF

Newly Elected Directors of Sinovac Hold the First Board Meeting

July 10, 2025 | businesswire.com

Final Reminder for SINOVAC Shareholders to Vote the WHITE Proxy Card "AGAINST" Misguided Proposals 1 and 2 - Nasdaq

July 9, 2025 | nasdaq.com

SINOVAC Board of Directors Strongly Denounces Deceptive and Illegal Claims by SAIF and the Imposter Former Board

July 9, 2025 | businesswire.com

SINOVAC Board of Directors Provides Update on Status of US$55.00 Special Cash Dividend Payment

July 9, 2025 | businesswire.com

SINOVAC Board of Directors Announces Adjournment of Special Meeting of Shareholders Until Appropriate Court Can Make a Final Decision on the Validity of the PIPE Shares

July 9, 2025 | businesswire.com

Appeal Decision By Eastern Caribbean Supreme Court Supports Right of Prime Success and Vivo Capital to Participate in Critical Sinovac Biotech Shareholder Vote

July 9, 2025 | businesswire.com

Sinovac Biotech Retains Support from Proxy Advisors Ahead of Crucial Vote

July 8, 2025 | tipranks.com

Final Reminder for SINOVAC Shareholders to Vote the WHITE Proxy Card "AGAINST" Misguided Proposals 1 and 2

July 7, 2025 | finance.yahoo.com

Final Reminder for SINOVAC Shareholders to Vote the WHITE Proxy Card “AGAINST” Misguided Proposals 1 and 2

July 7, 2025 | businesswire.com

Federal Court in Massachusetts Denies Vivo Capital’s Petition for Relief on SINOVAC

July 7, 2025 | finance.yahoo.com

Federal Court in Massachusetts Denies Vivo Capital's Petition for Relief on SINOVAC

July 7, 2025 | businesswire.com

Leading Independent Proxy Advisory Firm ISS Joins Glass Lewis in Recommending Shareholders Vote to Keep the Current SINOVAC Board in Place

July 3, 2025 | businesswire.com

United States District Court of Massachusetts Bars Activist 1Globe Capital and Jiaqiang Li From Making Further Materially Misleading Statements Regarding Sinovac

July 2, 2025 | businesswire.com

SAIF Partners: Now is Your Last Chance to Vote for Board Change at Sinovac

July 2, 2025 | businesswire.com

Sinovac Controlling Investors Ordered to Amend Disclosures

July 2, 2025 | news.bloomberglaw.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVA, IMVT, KYMR, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$20.75 +0.55 (+2.72%)

Closing price 04:00 PM Eastern

Extended Trading

$20.75 0.00 (0.00%)

As of 04:30 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Immunovant NASDAQ:IMVT

$14.84 +0.02 (+0.13%)

Closing price 04:00 PM Eastern

Extended Trading

$14.99 +0.15 (+1.00%)

As of 05:13 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Kymera Therapeutics NASDAQ:KYMR

$42.59 +0.24 (+0.57%)

Closing price 04:00 PM Eastern

Extended Trading

$42.59 0.00 (0.00%)

As of 05:13 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Sinovac Biotech NASDAQ:SVA

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time